Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-12-20
2005-12-20
Johannsen, Diana B. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C435S325000, C536S023500
Reexamination Certificate
active
06977147
ABSTRACT:
There is provided a method of testing squamous epithelial cells and a method of screening therapeutic agents for squamous cell carcinoma. That the base guanine at position 2128 (exon 17) of the FGFR3 gene is mutated to thymine in the cells of squamous cell carcinoma, or that the cells of squamous cell carcinoma produce an FGFR3 protein in which the amino acid glycine at position 697 is mutated to cysteine is utilized to facilitate the diagnosis and treatment of squamous cell carcinoma.
REFERENCES:
Grem, J.L. 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investigational New Drugs 18(4):299-313 (Nov. 2000).
Yee, C.J. et al. Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma. Journal of the National Cancer Institute 92(22):1848-1849 (Nov. 2000).
van Rhijn, B.W.G. et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Research 61(4):1265-1268 (Feb. 2001).
M. Chesi et al.; “Frequent Translocation T(4;14)(P16.3;Q32.3) in Multiple Myeloma is Associated with Increased Expression and Activating Mutations of Fibroblast Growth Factor Receptor 3”; Nature Genetics; vol. 16; pp. 260-264; 1997.
D. Cappellen et al.; “Frequent Activating Mutations of FGFR3 in Human Bladder and Cervix Carcinomas”; Nature Genetics; vol. 23; pp. 18-20; 1999.
J. H. Jang et al.; “Novel Transcripts of Fibroblast Growth Factor Receptor 3 Reveal Aberrant Splicing and Activation of Cryptic Splice Sequences in Colorectal Cancer”, Cancer Research 2000; 60(15); pp. 4049-4052.
D. Gospodarowicz et al.; “Purification of a Growth Factor for Ovarian Cells from Bovine Pituitary Glands”; Proc. Natl. Acad. Sci. USA; vol. 71; no. 6; pp. 2295-2299; 1974.
T. Nishimura et al.; “Identification of a Novel FGF, FGF-21, Preferentially Expressed in the Liver”; Biochem. Biophys. Acta.;1492; pp. 203-206; 2000.
D. Johnson et al.; “Structural and Functional Diversity in the FGF Receptor Multigene Family”; Advances in Cancer-Res.; 60:1; pp. 1-41; 1993.
J. Adnane et al.; “Bek and Flg, Two Receptors to Member of Te Fgf Family, are Amplified in Subsets of Human Breast Cancers”; Oncogene; vol. 6; pp. 659-663; 1991.
M. Muenke et al.; “Fibroblast-Growth-Factor Receptor Mutations in Human Skeletal Disorders”; Trend in Genetics; vol. 11; pp. 308-313; 1995.
E. W. Jabs; “Jackson-Weiss and Crouzon Syndromes are Allelic with Mutations in Fibroblast Growth Factor Receptor 2”; Nature Genetics; vol. 3; pp. 275-279; 1994.
X Li et al.; “Effect on Splicing of a Silent FGFR2 Mutation in Crouzon Syndrome”; vol. 9; pp. 232-233; 1995.
M. Muenke et al.; “A Common Mutation in the Fibroblast Growth Factor Receptor 1 Gene in Pfeiffer Syndrome”; vol. 8; pp. 269-274; 1994.
P. Rutland et al.; “Identical Mutations in the FGFR2 Gene Cause Both Pfeiffer and Crouzon Syndrome Phenotypes”; vol. 9; pp. 173-176; 1995.
E. Lajeunie et al.; “FGFR2 Mutations in Pfeiffer Syndrome”; Nature Genetics; vol. 9; p. 108; 1995.
U. Schell et al.; “Mutations in FGFR1 and FGFR2 Cause Familial and Sporadic Pfeiffer Syndrome”; vol. 4; pp. 323-328; 1995.
A. Wilkie et al.; “Apert Syndrome Results from Localized Mutations of FGFR2 and is Allelic with Crouzon Syndrome”; Nature Genetics; vol. 9; pp. 165-172; 1995.
R. Shiang et al.; “Mutations in the Transmembrane Domain of FGFR3 Cause the Most Common Genetic Form of Dwarfism, Achondroplasia”; Cell; vol. 78; pp. 335-342; 1994.
F. Rousseau et al.; “Mutations in the Gene Encoding Fibroblast Growth Factor Receptor-3 in Achondroplasia”; Nature; vol. 371; pp. 252-254; 1994.
P. Tavormina et al.; “Thanatophoric Dysplasia (Types I and II) Caused by Distinct Mutations in Fibroblast Growth Factor Receptor 3”; Nature Genetics; vol. 9; pp. 321-328; 1995.
G. Meyers et al.; “Fibroblast Growth Factor Receptor 3 (FGFR3) Transmembrane Mutation in Crouzon Syndrome with Acanthosis Nigricans”; Nature Genetics; vol. 11; pp. 462-464; 1995.
I. Mason et al.; “The Ins and Outs of Fibroblast Growth Factors”; Cell; vol. 78; pp. 547-552; 1994.
C. H. Heldin; “Dimerization of Cell Surface Receptors in Signal Transduction”; Cell. vol. 80; pp. 213-223; 1995.
D. M. Ornitz; FGFs, Heparan Sulfate and FGFRs: Complex Interactions Essential for Development; Bio Essays; vol. 22; pp. 108-112; 2000.
A. Isacchi et al.; “Complete Sequence of a Human Receptor for Acidic and Basic Fibroblast Growth Factors”; Nucleric Acids Research; vol. 18; p. 1906; 1990.
D. Johnson et al.; “Diverse Forms of a Receptor for Acidic and Basic Fibroblast Growth Factors”; Molecular and Cellular Biology; vol. 10; pp. 4728-4736; 1990.
C. Dionne et al.; “Cloning and Expression of Two Distinct High-Affinity Receptors Cross-Reacting with Acidic and Basic Fibroblast Growth Factors”; The EMBO Journal; vol. 9; pp. 2685-2692; 1990.
E. Houssaint et al.; “Related Fibroblast Growth Factor Receptor Genes Exist in the Human Genome”; Pro. Natl. Acad. Sci. USA; vol. 87; pp. 8180-8184, 1990.
K. Keegan et al.; “Isolation of an Additional Member of the Fibroblast Growth Factor Receptor Family, FGFR-3”; Proc. Natl. Acad. Sci. USA; vol. 88; pp. 1095-1099; 1991.
L. Thompson et al.; “A Gene Encoding a Fibroblast Growth Factor Receptor Isolated from the Huntington Disease Gene Region of Human Chromosome 4”; Genomics; vol. 1; pp. 1133-1142; 1991.
J. Partanen et al.; “FGFR-4, A Novel Acidic Fibroblast Growth Factor Receptor with a Distinct Expression Pattern”; The EMBO Journal; vol. 10, no. 6; pp. 1347-1354; 1991.
S. Vainikka et al.; “Fibroblast Growth Factor Receptor-4 Shows Novel Features in Genomic Structure, Ligand Binding and Signal Transduction”; The EMBO Journal; vol. 11, No. 12; pp. 4273-4280; 1992.
M. Jaye et al.; “Fibroblast Growth Factor Receptor Tyrosine Kinases; Molecular Analysis and Signal Transduction”; Biochem-Biophys-Acta.; vol. 1135; pp. 185-199; 1992.
D. Ornitz et al.; “Receptor Specificity of the Fibroblast Growth Factor Family”; Journal of Biological Chemistry; vol. 271, No. 25; pp. 15292-15297; 1996.
A. Avivi et al.; “A Novel Form of FGF Receptor-3 Using an Alternative Exon in the Immunoglobulin Domain III”; FEBS Letter; vol. 330; pp. 249-252; 1993.
B. Murgue et al.; “Identification of a Novel Variant Form of Fibroblast Growth Factor Receptor 3 (FGFR3IIIb) in Human Colonic Epithelium”; vol. 54; pp. 5206-5211; 1994.
D. Johnson et al.; “The Human Fibroblast Growth Factor Receptor Genes; A Common Sructural Arrangement Underlies the Mechanisms for Generating Receptor Forms that Differ in Their Third Immunoglobulin Domain”; Molecular and Cellular Biology; vol. 11; pp. 4627-4634; 1991.
S. Werner et al.; “Differential Splicing in the Extracellular Region of Fibroblast Growth Factor Receptor 1 Generates Receptor Variants with Different Ligand-Binding Specificities”; Molecular and Cellular Biology; vol. 12; pp. 82-88; 1992.
E. Shi et al.; “Control of Fibroblast Growth Factor Receptor Kinase Signal Transduction by Heterodimerization of Combinatorial Splice Variants”; Molecular and Cellular Biology; vol. 13; pp. 3907-3918; 1993.
A. Chellaiah et al.; “Fibroblast Growth Factor Receptor (FGFR) 3”; The Journal of Biological Chemistry; vol. 269; pp. 11620-11627; 1994.
M. Webster et al.; “FGFR Activation in Skeletal Disorders: Too Much of a Good Thing”; Trends in Genetics; vol. 13; pp. 178-182; 1997.
R. J. Gorlin; “Fibroblast Growth Factors, Their Receptors and Receptor Disorders”; Journal of Cranio-Maxillofacial Surgery; vol. 25; pp. 69-79;1997.
C. Drugan et al.; “Fibroblast Growth Factor Receptor Expression Reflec
Armstrong Kratz Quintos Hanson & Brooks, LLP
Johannsen Diana B.
Zeria Pharmaceutical Co. Ltd.
LandOfFree
Method of screening therapeutic or preventative agents for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of screening therapeutic or preventative agents for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of screening therapeutic or preventative agents for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3521901